Laboratory and clinical features at diagnosis of 776 ET patients enrolled in the MRC PT1-studies
| . | MPL mutant . | MPL negative . | P (vs V617F+) . | P (vs V617F−) . | |
|---|---|---|---|---|---|
| V617F+ . | V617F− . | ||||
| Number | 32* | 411 | 333 | ||
| Percentage (95% CI) | 4.1%(2.9-5.8) | 53.0% (49.4-56.5) | 42.9% (39.4-46.5) | ||
| Risk category, no. | |||||
| Low risk† | 0 | 26 | 31 | .2 | .09 |
| Intermediate risk‡ | 4 | 68 | 46 | .8 | 1.0 |
| High risk§ | 28 | 339 | 273 | .6 | .6 |
| Hydroxyurea plus aspirin | 13 | 168 | 139 | .9 | .8 |
| Anagrelide plus aspirin | 15 | 171 | 134 | ||
| Demographics | |||||
| Female, no. (%) | 17 (53%) | 255 (62%) | 192 (58%) | .3 | .7 |
| Male, no. (%) | 15 (47%) | 156 (38%) | 141 (42%) | ||
| Median age, y (10th-90th centile) | 67 (48-77) | 60 (39-77) | 52 (32-74) | .09 | < .001 |
| Median disease duration¶, mo. (10th-90th centile) | 18 (0-956) | 38 (0-1106) | 57 (0-2699) | .2 | .7 |
| Laboratory and clinical features at diagnosis | |||||
| Hemoglobin (g/L) | |||||
| Mean plus or minus SD | 133 ± 12 | 145 ± 14 | 135 ± 14 | <.001 | .3 |
| Median | 136 | 145 | 136 | ||
| (10th-90th centile) | (119-147) | (128-163) | (117-153) | ||
| White cells (×109/L) | |||||
| Mean plus or minus SD | 9.9 ± 2.4 | 10.6 ± 3.4 | 9.3 ± 2.7 | .2 | .2 |
| Median | 9.7 | 10.0 | 8.8 | ||
| (10th-90th centile) | (7.0-13.3) | (7.0-14.6) | (6.2-12.8) | ||
| Neutrophils (×109/L) | |||||
| Mean plus or minus SD | 6.7 ± 2.1 | 7.4 ± 3.0 | 6.2 ± 2.2 | .3 | .2 |
| Median | 6.9 | 6.8 | 5.8 | ||
| (10th-90th centile) | (4.4-9.6) | (4.2-11.0) | (3.8-9.1) | ||
| Platelet count (×109/L) | |||||
| Mean plus or minus SD | 1040 ± 272 | 900 ± 274 | 1032 ± 350 | .006 | .9 |
| Median | 962 | 840 | 963 | ||
| (10th-90th centile) | (752-1505) | (632-1221) | (666-1550) | ||
| Splenomegaly, no. (%) | 0/27 (0%) | 11/326 (3%) | 11/262 (4%) | .7 | .6 |
| Abnormal cytogenetics, no. (%) | 2/24‖ (8%) | 14/312 (4%) | 10/262 (4%) | .3 | .2 |
| . | MPL mutant . | MPL negative . | P (vs V617F+) . | P (vs V617F−) . | |
|---|---|---|---|---|---|
| V617F+ . | V617F− . | ||||
| Number | 32* | 411 | 333 | ||
| Percentage (95% CI) | 4.1%(2.9-5.8) | 53.0% (49.4-56.5) | 42.9% (39.4-46.5) | ||
| Risk category, no. | |||||
| Low risk† | 0 | 26 | 31 | .2 | .09 |
| Intermediate risk‡ | 4 | 68 | 46 | .8 | 1.0 |
| High risk§ | 28 | 339 | 273 | .6 | .6 |
| Hydroxyurea plus aspirin | 13 | 168 | 139 | .9 | .8 |
| Anagrelide plus aspirin | 15 | 171 | 134 | ||
| Demographics | |||||
| Female, no. (%) | 17 (53%) | 255 (62%) | 192 (58%) | .3 | .7 |
| Male, no. (%) | 15 (47%) | 156 (38%) | 141 (42%) | ||
| Median age, y (10th-90th centile) | 67 (48-77) | 60 (39-77) | 52 (32-74) | .09 | < .001 |
| Median disease duration¶, mo. (10th-90th centile) | 18 (0-956) | 38 (0-1106) | 57 (0-2699) | .2 | .7 |
| Laboratory and clinical features at diagnosis | |||||
| Hemoglobin (g/L) | |||||
| Mean plus or minus SD | 133 ± 12 | 145 ± 14 | 135 ± 14 | <.001 | .3 |
| Median | 136 | 145 | 136 | ||
| (10th-90th centile) | (119-147) | (128-163) | (117-153) | ||
| White cells (×109/L) | |||||
| Mean plus or minus SD | 9.9 ± 2.4 | 10.6 ± 3.4 | 9.3 ± 2.7 | .2 | .2 |
| Median | 9.7 | 10.0 | 8.8 | ||
| (10th-90th centile) | (7.0-13.3) | (7.0-14.6) | (6.2-12.8) | ||
| Neutrophils (×109/L) | |||||
| Mean plus or minus SD | 6.7 ± 2.1 | 7.4 ± 3.0 | 6.2 ± 2.2 | .3 | .2 |
| Median | 6.9 | 6.8 | 5.8 | ||
| (10th-90th centile) | (4.4-9.6) | (4.2-11.0) | (3.8-9.1) | ||
| Platelet count (×109/L) | |||||
| Mean plus or minus SD | 1040 ± 272 | 900 ± 274 | 1032 ± 350 | .006 | .9 |
| Median | 962 | 840 | 963 | ||
| (10th-90th centile) | (752-1505) | (632-1221) | (666-1550) | ||
| Splenomegaly, no. (%) | 0/27 (0%) | 11/326 (3%) | 11/262 (4%) | .7 | .6 |
| Abnormal cytogenetics, no. (%) | 2/24‖ (8%) | 14/312 (4%) | 10/262 (4%) | .3 | .2 |
One patient had both JAK2 V617F and MPL W515L mutations, and is included in the MPL-mutant column.
Includes 4 patients who subsequently enrolled in the intermediate-risk arm, and 10 in the high-risk arm.
Includes 4 patients who were previously enrolled in the low-risk arm and 25 who subsequently enrolled in the high-risk arm.
Includes 10 and 25 who were previously enrolled in the low- and intermediate-risk arms, respectively.
Refers to time elapsed between diagnosis and trial entry.
Comprises patient with MPL S505N and karyotype 45,XY,add(6)(q?15),-7 [6], 46,XY [25] and patient with MPL W515L and karyotype 47,XY,+14 [4], 46,XY [16], both at diagnosis.